Toronto Stock Exchange Symbol: LRI
LAVAL, QC, April 6 /CNW Telbec/ - LAB Research Inc. ("LRI" or "LAB Research") (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced the nominations of Mr. Kenneth Draper, Ph.D, D.A.B.T. as Senior Director Scientific Operations and Mr. James Noveroske, Ph.D. as Toxicology Scientific Consultant of LAB Research Canada.
Mr. Draper is a Diplomate of the American Board of Toxicology and has a Ph.D. in Microbial Genetics. He brings with him more than 25 years of experience in drug discovery and development at both scientific and management levels with Companies such as Schering Plough and Charles River Laboratories (CRL), including four years of providing regulatory advice to clients as a member of the CRL Navigator group. Mr. Draper has extensive experience with biologic drug entities, primate research, regulatory submissions and interaction with regulatory bodies. Mr. Draper is joining LAB Research Canada as its new Senior Director Scientific Operations.
Mr. James Noveroske has a Ph.D. in Reproductive Endocrinology and brings with him more than 40 years of experience in the industry at both scientific and management levels with Companies such as Merck, Searle, Bio Research, Sierra Biomedical, Ricerca and Icon. Mr. Noveroske has authored more than 600 reports and possesses extensive experience with regulatory submissions. Mr. Noveroske is joining LAB Research Canada as an exclusive preclinical Contract Research Toxicology Scientific Consultant.
"We are extremely proud to have Ken and Jim join LAB Research. Together they bring the right experience to complement an already strong team of scientists. These additions confirm our dedication and commitment in building the highest level possible of scientific expertise and counselling for our clients. Mr. Draper and Noveroske will undoubtedly play an important role in helping LAB Research Canada take full advantage of its expanded capabilities following the recent expansion of the site." stated Mr. Luc Mainville, Chief Executive Officer and President of LAB Research.
About LAB Research Inc.:
LAB Research is a Canadian global non-clinical contract research organization that provides contract research services to the pharmaceutical, biotechnology, agro-chemical, petro-chemical and industrial markets. LAB Research supports the development of its customers' products from three state-of-the-art facilities located in Canada, Denmark and Hungary.
LAB Research's shares trade on The Toronto Stock Exchange ("TSX") under the symbol "LRI", with 52.7 million shares outstanding.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB Research Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
SOURCE LAB RESEARCH INC.
For further information: For further information: visit LAB Research's website at www.labresearch.com, or contact: Luc Mainville, Chief Executive Officer, (450) 973-2240 (ext. 1206), firstname.lastname@example.org; Frédéric Dumais, Partner, Jasmin-Dumais Financial Communications, (514) 862-1251, email@example.com